Andy Batts
Long only, value, growth, momentum

DexCom Could Be A Potential Multi-Bagger

San Diego based DexCom (NASDAQ:DXCM), a player in the self-monitoring of blood glucose (SMBG) business, designs and manufactures continuous glucose monitoring (CGM) systems for use by diabetes patients and healthcare providers in hospitals. The continuous glucose monitoring market in the United States is likely to grow at an impressive CAGR of around 14.2% during 2010-2015, reports RNCOS.

Self-monitoring of blood glucose is now playing an important role in the treatment of diabetes mellitus. With an increasing number of patients using SMBG devices, the market for SMBG devices is about $4.5 billion worth of sales, primarily spread among only three companies - Abbott (NYSE:ABT), Medtronic (NYSE:MDT) and DexCom. In this article I'll delve deeper

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details